Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The board of Cline Scientific AB can today state that the minimum limit in the ongoing rights issue of SEK 5.5 million has been reached. By having the company's main owner and board members subscribe for shares together with external investors, the minimum limit that the board set to complete the issue has been reached. The rights issue is ongoing, after a previous extension, until Monday 31 July 2023. The issue is open to both existing shareholders and new investors to subscribe. The issue volume amounts to a maximum of SEK 9.25 million.
"As I have a strong belief in both the company's basic technology and the two projects we run, I do not want to risk the great values that exist being lost due to a lack of capital. In the long term, I see opportunities for a large return on the capital that I invest, which means that my wife and I take the risk of mortgaging our house to be able to invest additional funds in the company", says board member and largest owner Patrik Sundh.
The complete issue memorandum and registration forms are published on the Company's website www.clinescientific.com and Nordic Issuing's website www.nordic-issuing.se.
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser.
This information is information that Cline Scientific is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person set out above, at 2:27pm CEST on 26 July 2023.
For more information, please contact:
Hanne Evenbratt, CEO
Email: hanne.evenbratt@clinescientific.com
Phone: +46 703-585088